Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Presepsin as an Early Biomarker for Ventilator-associated Pneumonia (VAP) Diagnosis in COVID-19 Patients: a Prospective Double Blind Observational Study

NCT04840940 is registered in ClinicalTrials.gov with San Luigi Gonzaga Hospital as lead sponsor.

NCT NCT04840940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04840940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Presepsin as an Early Biomarker for Ventilator-associated Pneumonia (VAP) Diagnosis in COVID-19 Patients: a Prospective Double Blind Observational Study
Lead sponsor
San Luigi Gonzaga Hospital
Phase
Observational
Overall status
Unknown status
Start date
December 21, 2020
Completion date
December 21, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, ventilator associated pneumonia